Brokerages expect that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will announce earnings of ($0.46) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Xenon Pharmaceuticals’ earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.48). Xenon Pharmaceuticals reported earnings per share of ($0.45) in the same quarter last year, which suggests a negative year-over-year growth rate of 2.2%. The firm is expected to announce its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.98) per share for the current year, with EPS estimates ranging from ($2.18) to ($1.76). For the next year, analysts anticipate that the firm will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.39) to ($1.60). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.06).
A number of research analysts recently commented on XENE shares. Zacks Investment Research downgraded shares of Zafgen from a “buy” rating to a “hold” rating in a report on Saturday, July 20th. BidaskClub downgraded shares of Xencor from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 11th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $15.00.
Shares of NASDAQ:XENE traded up $0.15 during trading on Tuesday, reaching $9.52. The company’s stock had a trading volume of 9,888 shares, compared to its average volume of 89,050. The company has a quick ratio of 17.57, a current ratio of 17.57 and a debt-to-equity ratio of 0.18. Xenon Pharmaceuticals has a 12 month low of $5.41 and a 12 month high of $15.92. The company’s 50 day moving average price is $9.74. The stock has a market cap of $245.36 million, a PE ratio of -7.16 and a beta of 1.34.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Sphera Funds Management LTD. lifted its stake in Xenon Pharmaceuticals by 18.7% in the first quarter. Sphera Funds Management LTD. now owns 533,655 shares of the biopharmaceutical company’s stock worth $5,422,000 after purchasing an additional 84,171 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in Xenon Pharmaceuticals in the fourth quarter worth about $828,000. Northern Trust Corp lifted its stake in Xenon Pharmaceuticals by 18.9% in the fourth quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,948 shares during the last quarter. Two Sigma Investments LP lifted its stake in Xenon Pharmaceuticals by 161.5% in the fourth quarter. Two Sigma Investments LP now owns 200,261 shares of the biopharmaceutical company’s stock worth $1,264,000 after purchasing an additional 123,676 shares during the last quarter. Finally, BlackRock Inc. bought a new stake in Xenon Pharmaceuticals in the fourth quarter worth about $1,790,000. 68.88% of the stock is owned by institutional investors and hedge funds.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.
Read More: What is a management fee?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.